08/17/2026
Proud to share a new publication in the American Journal of Clinical Dermatology: our one-year study of ruxolitinib 1.5% cream in 103 teens with mild-to-moderate eczema found it was well tolerated, with no serious safety signals and skin involvement dropping from ~9% of the body to 2.5% by week 8 and holding steady through 52 weeks. Grateful to the patients and families who participated and to my research team. π Open access: https://link.springer.com/article/10.1007/s40257-026-01043-0 β funded by Incyte Corporation.
Midwest Allergy Sinus Asthma SC Sneeze, Wheeze & Itch Associates
Background Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged β₯ 2 years with mild-to-moderate atopic dermatitis. Objective We aimed to further investigate the safety and efficacy of ruxolitinib cream in adolescents with atopic dermatitis in an open-label study. Methods ...